Logo Image
Opinion|Videos|February 14, 2025

MCL Therapy Selection and Sequencing

Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.

Episodes in this series
  1. What treatment- and patient-specific factors do you consider when determining induction therapy for a treatment-naive patient with MCL (eg, aggressive vs less aggressive)?
  2. How do you sequence therapies for patients with MCL and how does prior therapy exposure influence your subsequent choice of treatments?

Related Content